Menu
Not yet recruiting NCT05752318

Analysis of the Persistence, Reservoir and HIV Latency

Observational HIV Infected Individuals Informed Consent

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: HIV Infected Individuals, Informed Consent. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

APRIL Study: Analysis of the Persistence, Reservoir and HIV Latency

Overview

The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.

Primary outcome measures

  • HIV-Flow [Time frame: 1 day]

Eligibility criteria

Inclusion criteria

  • HIV-infection
  • Adults (>18 years)
  • Social insurance
  • Informed consent

Exclusion criteria

  • HIV-uninfected
  • <18 years
  • Lack of social insurance
  • Lack or withdraw of consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05752318 · 8825

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗